Theory Paper IIDrNB Cardiology – Theory Notes
ASPIRIN IN PRIMARY PREVENTION: CURRENT STATUS
IINTRODUCTION AND THE CONTEMPORARY RISK-BENEFIT SHIFT
- The Narrowed Therapeutic Window: Low-dose Aspirin (75 to 100 mg once daily) irreversibly inhibits platelet cyclooxygenase-1 (COX-1), suppressing prothrombotic Thromboxane A2 generation for the 7-to-10-day lifespan of the platelet. While Aspirin remains an indisputable Class I cornerstone in secondary prevention (prior MI, PCI, CABG, or ischemic stroke), its role in primary prevention has been sharply curtailed.
- Why the Paradigm Changed: Widespread adoption of high-intensity statins, modern antihypertensives, SGLT2 inhibitors/GLP-1 receptor agonists, and smoking cessation has lowered baseline first-time ASCVD event rates by 40 to 50 percent over the past three decades; consequently, the small absolute reduction in non-fatal MI (~1 to 2 events per 1,000 patient-years) is matched or exceeded by the absolute increase in major gastrointestinal and intracranial bleeding (~1 to 2 events per 1,000 patient-years), with zero reduction in cardiovascular or all-cause mortality.
IICURRENT CLINICAL GUIDELINE RECOMMENDATIONS
- Adults Aged 40 to 59 Years (USPSTF 2022 Grade C) / 40 to 70 Years (ACC/AHA 2019 Class IIb): Low-dose Aspirin (75 to 100 mg daily) may be considered selectively via shared decision-making only in individuals with a high 10-year ASCVD risk (10 percent or greater; >20 percent in many consensus algorithms) who have low bleeding risk and subclinical atherosclerosis modifiers (such as Coronary Artery Calcium [CAC] score >=100 Agatston units or elevated Lipoprotein(a)).
- Older Adults — Age >=60 Years (USPSTF 2022 Grade D) and Age >70 Years (ACC/AHA 2019 Class III: Harm): Routine initiation of low-dose Aspirin for primary prevention is not recommended at age 60 years or older and is contraindicated (Class III: Harm) in adults over 70 years of age, because major extracranial and intracranial bleeding risk rises exponentially with age and outweighs any ischemic benefit.
- Any Age with Increased Bleeding Risk (ACC/AHA Class III: Harm): Strictly contraindicated in patients with prior peptic ulcer disease or GI hemorrhage, anemia, thrombocytopenia, chronic kidney disease, chronic liver disease, uncontrolled hypertension, or concomitant use of NSAIDs, corticosteroids, or oral anticoagulants.
- Diabetes Mellitus Without Established ASCVD (ESC 2023 Class IIb): Diabetes alone is not an automatic indication for Aspirin; low-dose Aspirin (75 to 100 mg/day) may be considered (Class IIb) only in diabetic patients at high or very-high cardiovascular risk (e.g., long diabetes duration >=10 years with target-organ damage or multiple risk factors) in the absence of bleeding contraindications.
IIITHE THREE LANDMARK 2018 RANDOMIZED TRIALS
| Landmark Trial (2018) | Target Population & Sample Size | Primary Efficacy Outcome (Ischemic Events) | Primary Safety Outcome (Major Bleeding) | Definitive Clinical Verdict |
|---|---|---|---|---|
| ARRIVE (Lancet 2018) | 12,546 Moderate-Risk Non-Diabetic Adults (men >=55 yr, women >=60 yr) | Neutral: 4.29% vs. 4.48% (HR 0.96; p = 0.60) | 2.1-fold increase in GI bleeding (0.97% vs. 0.46%; HR 2.11) | Ineffective in moderate-risk non-diabetic primary prevention |
| ASCEND (NEJM 2018) | 15,480 Adults with Diabetes Mellitus (>=40 yr) and no baseline CVD | 12% RRR in serious vascular events (8.5% vs. 9.6%; ARR 1.1%, NNT = 91) | 29% increase in major bleeding (4.1% vs. 3.2%; ARI 0.9%, NNH = 112) | Ischemic benefit offset by major bleeding; not routine for all diabetics |
| ASPREE (NEJM 2018) | 19,114 Healthy Elderly Adults (>=70 yr, or >=65 yr US Black/Hispanic) | No benefit on disability-free survival or MACE (HR 0.95) | 38% increase in major hemorrhage (HR 1.38) + higher all-cause mortality (HR 1.14) | Harmful (Class III) in healthy elderly >=70 years |
IVPRECISION IMAGING GUIDANCE AND THE INDIAN CLINICAL CONTEXT
- Coronary Artery Calcium (CAC)-Guided Aspirin Allocation: Because clinical risk calculators poorly discriminate true plaque burden, CAC scoring serves as the premier tie-breaker in borderline/intermediate-risk patients aged 40 to 60 years:
- CAC = 0: Very low 10-year event rate (<1% to 1.5%); Aspirin causes net harm and is avoided.
- CAC >= 100 Agatston Units (or Non-Obstructive Plaque on Coronary CTA): Identifies patients with established subclinical coronary atherosclerosis who achieve a favorable net reduction in myocardial infarction from Aspirin 75 mg/day + High-Intensity Statin (provided bleeding risk is low).
- Targeted Application in the Indian Phenotype: Recognizing that South Asians develop premature CAD a decade earlier than Western populations, Indian expert practice favours reserving primary-prevention Aspirin for adults under 60 years of age with very high lifetime risk—specifically those with CAC >=100, familial hypercholesterolemia, severely elevated Lipoprotein(a) (>50 mg/dL) with multiple risk factors, or high-risk diabetes with microangiopathy—while routinely co-prescribing gastroprotection when indicated due to high endemic H. pylori prevalence.
Key references
- Arnett DK, Blumenthal RS, Albert MA, et al.: 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, Circulation, 2019.
- US Preventive Services Task Force (Davidson KW, Barry MJ, Mangione CM, et al.): Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement, JAMA, 2022.
- Cainzos-Achirica M, Miedema MD, McEvoy JW, et al.: Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study, Circulation, 2020.
meritmedscript.comDr. Sidhartha Mullapudi
